VectivBio

上市后再融资

VectivBio Holding AG operates as a holding company. The Company focuses on developing medicines that target the biological root cause of rare conditions to achieve disease-modification.In May 2023, Ironwood Pharmaceuticals Inc entered into a definitive agreement to acquire VectivBio.In June 2022, VectivBio Holding AG announced the launch of a follow-on public offering of its ordinary shares.In September 2021, VectivBio Holding AG had acquired Comet Therapeutics Inc.In August 2021, VectivBio Holding AG had announced to acquire Comet Therapeutics Inc.In October 2022, VectivBio Holding AG had closed an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share and total gross raised to $125 Million.In October 2022, VectivBio Holding AG had announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share raising $125 Million.In June 2022, VectivBio Holding AG clos

https://vectivbio.com/

470305

基本信息

公司全称

VectivBio Holding AG
类型

临床阶段生物新药研发商
产业领域

医药研发/制造、化学&生物药
公司人数

15~50人
地址

c/o Therachon AG Aeschenvorstadt 36 BASEL BASEL-STADT 4051; CH;
联系电话
邮箱

info@vectivbio.com
成立时间

2005-01-01

投融资

2022-06-29

IPO后其他轮次

Forbion Capital Partners
2022-06-29

上市后再融资

Forbion Capital Partners
2021-04-08

IPO

未透露
2020-10-15

未公开

未透露
2020-10-15

未公开

鱼鹰资管

Tekla Capital Management

Eventide Asset Management

奥博资本

Inserm Transfer Initiative

Cowen Healthcare Investments

诺和诺德

Versant Ventures

Bpifrance

Surveyor Capital
2020-01-07

A轮

Inserm Transfer Initiative

BPI

Versant Ventures

Cowen Healthcare Investments

OrbiMed

Novo Holdings
2020-01-07

A轮

奥博资本

Inserm Transfer Initiative

Cowen Healthcare Investments

诺和诺德

Versant Ventures

BPI
2019-01-01

未公开

辉瑞
加载更多

VectivBio

基本信息

投融资

相关投融资企业